Clinical Trials on Recurrent Lung Non-Small Cell Carcinoma

Total 8786 results

AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Ernesto Maranzano,MD; Fabio Trippa,MD

Completed

Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer (START-NEW-ERA)

Locally Advanced Lung Non-Small Cell Carcinoma

Italy
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca UK Limited

Recruiting

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Breast Cancer | Non-small Cell Lung Carcinoma

United States, Spain, France, United Kingdom
Menoufia University

Completed

Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients

Radiation Therapy | Non-Small Cell Carcinoma of Lung, TNM Stage 4

Egypt
Fundación GECP

Recruiting

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Carcinoma Bronchiogenic Stage III

Spain
Emory University
National Cancer Institute (NCI)

Recruiting

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Allist Pharmaceuticals, Inc.

Not yet recruiting

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD)

Non-small Cell Lung Carcinoma
Centre Leon Berard

Terminated

Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor (GFPC_01-14)

Non-small-cell Lung Carcinoma

France
Genzyme, a Sanofi Company

Completed

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Non-Small-Cell Lung Carcinoma

United States, France, Italy, Korea, Republic of, Peru, Spain, United Kingdom, Philippines, China, Germany, Hong Kong, Argentina, Austria, Canada, Israel, Taiwan, Mexico, Thailand, Belgium, Australia, Singapore, Netherlands
Genzyme, a Sanofi Company

Completed

Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Non-Small-Cell Lung Carcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Duke University
Regeneron Pharmaceuticals

Not yet recruiting

TOP 2301: Neoadjuvant Chemo for NSCLC

Non Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Henan Cancer Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Non-small Cell Lung Cancer

China
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Non Small Cell Lung Cancer

China
Yonsei University

Not yet recruiting

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer)

Non-small Cell Lung Cancer

Korea, Republic of
University of California, Irvine

Recruiting

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

Non Small Cell Lung Cancer

United States
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Huashan Hospital

Recruiting

[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer

Non-small Cell Lung Cancer

China
Vastra Gotaland Region

Not yet recruiting

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease (ANDROMEDA)

Non Small Cell Lung Cancer

Sweden
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Recruiting

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Non-small Cell Lung Cancer

China
CellSight Technologies, Inc.
University of Iowa Hospitals & Clinics

Not yet recruiting

Test-retest Evaluation of [18F]F-AraG PET

Non-small Cell Lung Cancer

United States
Muhammad Furqan

Recruiting

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Recruiting

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

Poland, United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Canada, Lithuania, Norway, Italy, Czechia, Estonia, Portugal
Memorial Sloan Kettering Cancer Center
EARLY Labs

Recruiting

Using Urine Samples to Identify Lung Cancer

Non Small Cell Lung Cancer

United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Dizal Pharmaceuticals

Recruiting

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Non-small Cell Lung Cancer

China
Centre hospitalier de l'Université de Montréal...

Recruiting

Dietary Intervention for NSCLC Patients Treated With ICI

Non Small Cell Lung Cancer

Canada
Transgene

Recruiting

A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)

Non-small Cell Lung Cancer

France
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Canada, Turkey, Brazil, Spain, France, Germany, Australia, Italy, Belgium, Mexico
Peking Union Medical College Hospital

Recruiting

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
OncoC4, Inc.
BioNTech SE

Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Non Small Cell Lung Cancer

United States, Belgium, Canada, France, Germany, Italy, Spain, China, Korea, Republic of, Netherlands, Turkey, United Kingdom, Australia
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Shanghai Proton and Heavy Ion Center

Recruiting

Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Chang Gung Memorial Hospital

Not yet recruiting

Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy

Non-small Cell Lung Cancer
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Non Small Cell Lung Cancer

China
Fuzhou General Hospital

Not yet recruiting

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Non-small Cell Lung Cancer

China
Instituto Nacional de Cancerologia de Mexico

Recruiting

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (METLUNG)

Non Small Cell Lung Cancer

Mexico
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan

Clinical Trials on Recurrent Lung Non-Small Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations